A

Aldeyra Therapeutics
D

ALDX

5.16000
USD
-0.28
(-5.06%)
مغلق
حجم التداول
46,280
الربح لكل سهم
-1
العائد الربحي
-
P/E
-5
حجم السوق
309,061,234
أصول ذات صلة
A
AMRN
-0.070
(-0.45%)
15.450 USD
B
BLDP
0.03500
(1.67%)
2.13000 USD
C
CAPR
0.59000
(9.12%)
7.06000 USD
C
CLRB
-0.18000
(-3.42%)
5.09000 USD
E
ESCA
0.030
(0.23%)
12.820 USD
G
GERN
-0.02000
(-1.57%)
1.25500 USD
GILD
GILD
3.000
(2.65%)
116.210 USD
H
HALO
-0.540
(-0.92%)
58.230 USD
I
IONS
0.100
(0.24%)
42.240 USD
NVS
NVS
0.260
(0.22%)
117.680 USD
O
OPK
-0.03000
(-2.15%)
1.36500 USD
S
SLDB
0.34000
(5.11%)
7.00000 USD
VRTX
VRTX
-2.89
(-0.61%)
469.58 USD
C
CBIO
0.280
(2.16%)
13.260 USD
المزيد
الأخبار المقالات

العنوان: Aldeyra Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.